Mirum Pharmaceuticals Dirección
Dirección controles de criterios 2/4
El CEO de Mirum Pharmaceuticals' es Chris Peetz , nombrado en Mar 2019, tiene una permanencia de 5.08 años. compensación anual total es $6.45M, compuesta por 10.2% salario y 89.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.55% de las acciones de la empresa, por valor de $6.34M. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 3.7 años, respectivamente.
Información clave
Chris Peetz
Chief Executive Officer (CEO)
US$6.5m
Compensación total
Porcentaje del salario del CEO | 10.2% |
Permanencia del CEO | 5.2yrs |
Participación del CEO | 0.6% |
Permanencia media de la dirección | 2.3yrs |
Promedio de permanencia en la Junta Directiva | 3.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Apr 22Mirum Pharmaceuticals: Advancing On Several Key Fronts
Mar 05There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price
Dec 26What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You
Jun 10Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts
Apr 18Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU
Oct 14Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth
Aug 17Mirum Pharmaceuticals announces $80M stock offering
Aug 09Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent
May 27Is Mirum Pharmaceuticals (NASDAQ:MIRM) In A Good Position To Invest In Growth?
Apr 22Mirum Pharmaceuticals Gets The 'Thumbs Up'
Dec 16Need To Know: Analysts Just Made A Substantial Cut To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates
Nov 25Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$159m |
Dec 31 2023 | US$6m | US$660k | -US$163m |
Sep 30 2023 | n/a | n/a | -US$164m |
Jun 30 2023 | n/a | n/a | -US$176m |
Mar 31 2023 | n/a | n/a | -US$129m |
Dec 31 2022 | US$4m | US$624k | -US$136m |
Sep 30 2022 | n/a | n/a | -US$42m |
Jun 30 2022 | n/a | n/a | -US$53m |
Mar 31 2022 | n/a | n/a | -US$70m |
Dec 31 2021 | US$4m | US$600k | -US$84m |
Sep 30 2021 | n/a | n/a | -US$179m |
Jun 30 2021 | n/a | n/a | -US$153m |
Mar 31 2021 | n/a | n/a | -US$132m |
Dec 31 2020 | US$3m | US$512k | -US$103m |
Sep 30 2020 | n/a | n/a | -US$84m |
Jun 30 2020 | n/a | n/a | -US$78m |
Mar 31 2020 | n/a | n/a | -US$68m |
Dec 31 2019 | US$6m | US$458k | -US$53m |
Sep 30 2019 | n/a | n/a | -US$61m |
Dec 31 2018 | US$385k | US$32k | -US$26m |
Compensación vs. Mercado: La compensación total de Chris($USD6.45M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.39M).
Compensación vs. Ingresos: La compensación de Chris ha aumentado mientras la empresa no es rentable.
CEO
Chris Peetz (44 yo)
5.2yrs
Permanencia
US$6,451,720
Compensación
Mr. Christopher Peetz, also known as Chris, serves as Entrepreneur-in-Residence at Frazier Management, L.L.C since May 30, 2017. He also serves as Entrepreneur-in-Residence at Frazier Life Sciences Managem...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
CEO & Director | 5.2yrs | US$6.45m | 0.64% $ 7.4m | |
COO & President | 4.1yrs | US$2.37m | 0.042% $ 495.4k | |
Chief Financial Officer | less than a year | US$4.69m | 0.030% $ 346.6k | |
Chief Scientific Officer | less than a year | US$1.51m | 0.20% $ 2.3m | |
Vice President of Investor Relations and Finance | no data | sin datos | sin datos | |
Chief Compliance Officer | 4.1yrs | sin datos | sin datos | |
Senior Vice President of Human Resources | 5.3yrs | sin datos | sin datos | |
Consultant | less than a year | US$1.98m | 0.033% $ 379.4k | |
Chief Development Officer | 5.4yrs | US$1.51m | 0.20% $ 2.3m | |
Senior vice President of Quality | 2.3yrs | sin datos | sin datos | |
Senior Vice President of Technical Operations | 1.3yrs | sin datos | sin datos | |
Chief Medical Officer | less than a year | sin datos | sin datos |
2.3yrs
Permanencia media
53.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de MIRM se considera experimentado (2.3 años antigüedad media).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
CEO & Director | no data | US$6.45m | 0.64% $ 7.4m | |
Independent Director | 5.5yrs | US$401.75k | 0% $ 0 | |
Independent Director | 4.8yrs | US$426.75k | 0.021% $ 247.6k | |
Independent Non-Executive Chairman of the Board | 5.2yrs | US$451.75k | 0.81% $ 9.5m | |
Independent Director | 4.9yrs | US$421.75k | 0.014% $ 167.1k | |
Independent Director | 1.1yrs | US$671.53k | 0% $ 0 | |
Independent Director | 2.8yrs | US$411.75k | 0% $ 0 | |
Independent Director | 1.5yrs | US$194.47k | 0% $ 0 | |
Independent Director | 1.9yrs | US$411.75k | 0% $ 0 |
3.8yrs
Permanencia media
57yo
Promedio de edad
Junta con experiencia: La junta directiva de MIRM se considera experimentada (3.7 años de antigüedad promedio).